首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1471972

色素減退症治療市場規模和預測、全球和地區佔有率、趨勢和成長機會分析報告範圍：按治療、疾病適應症、最終用戶和地理位置

Hypopigmentation Disorder Treatment Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment, Disease Indication, End User, and Geography

出版日期: 2024年03月21日 | 出版商:

The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格

簡介目錄

色素減退症治療市場預計將從 2023 年的 44 億美元成長到 2031 年的 67 億美元；預計2023年至2031年複合年成長率為5.41%。

色素沉著不足症的治療包括皮膚缺乏正常色素沉著的皮膚狀況，從而導致較淺或白色的斑塊。幾種色素沉著不足的治療方法旨在恢復或平衡膚色。局部皮質類固醇、光療和脫色是常見的方法。雷射療法和細胞療法等新興技術已被證明有望使患者受影響的區域重新著色。色素減退性疾病的治療計劃是根據妊娠高血壓症候群、白斑症或白化病等特定疾病量身定做的。

色素減退症的盛行率不斷增加以及皮膚病學研究的進步推動了色素減退症治療市場的成長。

色素沉著不足疾病的盛行率不斷上升，例如白斑症和白化症。例如，根據 2021 年 7 月《安寧療護年鑑》發布的資料，全球白斑症盛行率在0.1% 至8% 之間，白斑症與一些自體免疫性和非自體免疫疾病有關，人們對白斑症的認知有所提高，並儘早發現白斑症診斷有助於增加尋求治療介入的患者群體。此外，人們美容意識的高漲以及這些人美觀的皮膚進一步推動了市場的發展，人們尋求治療色素沉著不足的疾病。

其次，皮膚科研究和技術的進步導致了創新療法的發展，包括光療、局部療法和外科手術，提高了可用解決方案的功效和範圍。此外，與色素減退症治療市場規模相關的有利報銷政策和擴大治療策略有助於市場成長。製藥公司和研究機構之間的合作和夥伴關係加速了新療法的開發。此外，全球人口老化和皮膚相關疾病的增加增加了對色素沉著不足疾病治療的需求。總體而言，色素減退症治療市場是動態的，並且對不斷變化的患者需求、技術創新和醫療保健行業內的協作努力做出反應。

色素減退症治療市場分析是透過考慮以下部分進行的：基於治療、疾病適應症和最終用戶。依治療方法，市場分為基本外用藥物、雷射療法、化學換膚、微晶煥膚、光療等。根據疾病適應症，市場分為白糠疹、白斑症、白化症和發炎後色素沉著不足。就最終用戶而言，市場分為美容診所、皮膚科中心和醫院。色素減退症治療市場報告的地理範圍包括北美（美國、加拿大和墨西哥）、歐洲（英國、德國、法國、義大利、西班牙和歐洲其他地區）、亞太地區（中國、日本、印度、澳洲）、韓國和亞太地區其他地區）、中東和非洲（阿拉伯聯合大公國、沙烏地阿拉伯、南非以及中東和非洲其他地區）以及南美洲和中美洲（巴西、阿根廷以及中南部和中部其他地區）美國）。

就收入而言，由於美國色素減退症患者的盛行率較高，北美在色素減退症治療市場佔有率中佔據主導地位。此外，對色素沉著不足治療藥物的需求、白斑等色素沉著疾病盛行率的增加以及對色素沉著不足疾病相關意識的提高等因素進一步推動了市場的成長。由於關鍵產品的推出、製造商或市場參與者的高度集中以及知名競爭對手之間的聯盟和收購等多種因素，美國色素減退症治療市場正在不斷成長。此外，關鍵參與者的策略存在使美國成為色素沉著不足疾病治療市場成長的關鍵國家。例如，根據《美國皮膚病學會雜誌》2020 年 12 月的數據，白斑全球盛行率約為 0.5%-2%，報告的發生率因地理位置而異。

歐洲
- 德國
- 法國
- 義大利
- 西班牙
- 英國
- 歐洲其他地區
亞太
- 澳洲
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
南美洲和中美洲
- 巴西
- 阿根廷
- 南美洲和中美洲其他地區

第 11 章：產業格局

併購
協議、合作、合資企業
新產品發布
擴張和其他策略發展

第 12 章：競爭格局

關鍵參與者的熱圖分析
公司定位與專注

第 13 章：色素沉著減退症治療市場 - 主要公司簡介

Allergan
SkinCeuticals
Pierre Fabre
Episciences, Inc
RXi Pharmaceuticals Corporation
Obagi Cosmeceuticals LLC
Incyte
L'oreal Paris
CLINUVEL PHARMACEUTICALS LTD
STRATA Skin Sciences
TeVido BioDevices, Inc.
Courage + Khazaka electronic GmbH
AVITA Medical
Galderma S.A.
Vital Esthetique

第 14 章：附錄

簡介目錄

Product Code: TIPRE00004312

The hypopigmentation disorder treatment market is expected to grow from US$ 4.4 billion in 2023 to US$ 6.7 billion by 2031; it is anticipated to record a CAGR of 5.41% from 2023 to 2031.

Hypopigmentation disorder treatment includes skin conditions where the skin lacks normal pigmentation, which results in lighter or white patches. Several therapeutics of hypopigmentation aim to restore or balance skin color. topical corticosteroids, Phototherapy, and depigmentation are common approaches. Emerging technologies, such as laser therapy and cell-based treatments, are shown to promise in repigmenting affected areas of patients. Treatment plans for hypopigmentary disorders are tailored based on specific disorders such as PIH, vitiligo or albinism.

Increasing prevalence of hypopigmentary disorders and advancements in dermatological research drive the growth of the Hypopigmentation Disorder Treatment market.

The rising prevalence of hypopigmentation disorders, such as vitiligo and albinism. For instance, according to the data published in Annals of Palliative Medicine in July 2021, prevalence of vitiligo was reported to range from 0.1% to 8% globally, and vitiligo has been linked to some autoimmune and non-autoimmune diseases and increased awareness and early diagnosis contribute to the increasing patient pool seeking therapeutic interventions. Additionally, a surge in cosmetic consciousness people and the aesthetically pleasing skin among those people further propel the market, with individuals seeking treatments to address hypopigmentation- disorders.

Secondly, advancements in dermatological research and technology resulted in the development of innovative treatments, including phototherapy, topical therapies, and surgical procedures, enhancing the efficacy and scope of available solutions. Moreover, favorable reimbursement policies and expanding treatment strategy related to hypopigmentation disorder treatment market size contribute to market growth. Collaboration and partnerships among pharmaceutical companies and research institutions accelerate the development of novel therapies. Furthermore, the global aging population and the associated increase in skin-related disorders amplify the demand for hypopigmentation disorder treatments. Overall, the hypopigmentation disorder treatment market is dynamic and responsive to evolving patient needs, technological innovations, and collaborative efforts within the healthcare industry.

The hypopigmentation disorder treatment market analysis has been carried out by considering the following segments: based on treatment, disease indication, and end user. By treatment, the market is classified into basic topical drugs, laser therapy, chemical peels, microdermabrasion, phototherapy, and others. Based on disease indication, the market is segmented into pityriasis alba, vitiligo, albinism, and post-inflammatory hypopigmentation. In terms of end user, the market is classified into aesthetics clinics, dermatology centers and hospitals. The geographic scope of the hypopigmentation disorder treatment market report includes North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

In terms of revenue North America dominated the hypopigmentation disorder treatment market share owing to a higher prevalence of patients suffering from hypo pigmentary disorders in the US. Furthermore, factors like demand for hypopigmentation therapeutics, increasing prevalence of pigmentation disorder such as vitiligo and rising awareness related to hypopigmentation disorders is further driving the market growth. The US hypopigmentation disorder treatment market is growing owing to various factors such as key product introductions, a high concentration of manufacturers or market players, and alliances and acquisitions among prominent competitors. Furthermore, the strategic presence of key players positions US is a key country for the Hypopigmentation Disorder Treatment Market growth. For instance, according to the Journal of American Academy of Dermatology in December 2020, Vitiligo global prevalence is ~0.5%-2%, with reported rates varying geographically .

1. Introduction

1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness Analysis

3. Research Methodology

4. Hypopigmentation Disorder Treatment Market Landscape

4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain

5. Hypopigmentation Disorder Treatment Market - Key Market Dynamics

5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints

6. Hypopigmentation Disorder Treatment Market - Global Market Analysis

6.1 Hypopigmentation Disorder Treatment - Global Market Overview
6.2 Hypopigmentation Disorder Treatment - Global Market and Forecast to 2031

7. Hypopigmentation Disorder Treatment Market - Revenue Analysis (USD Million) - By Treatment, 2021-2031

7.1 Overview
7.2 Topical Drugs
7.3 Laser Therapy
7.4 Chemical Peels
7.5 Microdermabrasion
7.6 Phototherapy
7.7 Skin Grafting
7.8 Pigment cell transplantation
7.9 Others

8. Hypopigmentation Disorder Treatment Market - Revenue Analysis (USD Million) - By Disease Indication, 2021-2031

8.1 Overview
8.2 Vitiligo
8.3 Albinism
8.4 Hypopigmented/depigmented scars
8.5 Melasma
8.6 Post-Inflammatory Hypopigmentation (PIH)
8.7 Others

9. Hypopigmentation Disorder Treatment Market - Revenue Analysis (USD Million) - By End User, 2021-2031

9.1 Overview
9.2 Hospitals
9.3 Aesthetic Clinics
9.4 Dermatology Centers
9.5 Others

10. Hypopigmentation Disorder Treatment Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

10.1 North America
- 10.1.1 North America Hypopigmentation Disorder Treatment Market Overview
- 10.1.2 North America Hypopigmentation Disorder Treatment Market Revenue and Forecasts to 2031
- 10.1.3 North America Hypopigmentation Disorder Treatment Market Revenue and Forecasts and Analysis - By Treatment
- 10.1.4 North America Hypopigmentation Disorder Treatment Market Revenue and Forecasts and Analysis - By Disease Indication
- 10.1.5 North America Hypopigmentation Disorder Treatment Market Revenue and Forecasts and Analysis - By End User
- 10.1.6 North America Hypopigmentation Disorder Treatment Market Revenue and Forecasts and Analysis - By Countries
  - 10.1.6.1 United States Hypopigmentation Disorder Treatment Market
    - 10.1.6.1.1 United States Hypopigmentation Disorder Treatment Market, by Treatment
    - 10.1.6.1.2 United States Hypopigmentation Disorder Treatment Market, by Disease Indication
    - 10.1.6.1.3 United States Hypopigmentation Disorder Treatment Market, by End User
  - 10.1.6.2 Canada Hypopigmentation Disorder Treatment Market
    - 10.1.6.2.1 Canada Hypopigmentation Disorder Treatment Market, by Treatment
    - 10.1.6.2.2 Canada Hypopigmentation Disorder Treatment Market, by Disease Indication
    - 10.1.6.2.3 Canada Hypopigmentation Disorder Treatment Market, by End User
  - 10.1.6.3 Mexico Hypopigmentation Disorder Treatment Market
    - 10.1.6.3.1 Mexico Hypopigmentation Disorder Treatment Market, by Treatment
    - 10.1.6.3.2 Mexico Hypopigmentation Disorder Treatment Market, by Disease Indication
    - 10.1.6.3.3 Mexico Hypopigmentation Disorder Treatment Market, by End User

Note - Similar analysis would be provided for below mentioned regions/countries

10.2 Europe
- 10.2.1 Germany
- 10.2.2 France
- 10.2.3 Italy
- 10.2.4 Spain
- 10.2.5 United Kingdom
- 10.2.6 Rest of Europe
10.3 Asia-Pacific
- 10.3.1 Australia
- 10.3.2 China
- 10.3.3 India
- 10.3.4 Japan
- 10.3.5 South Korea
- 10.3.6 Rest of Asia-Pacific
10.4 Middle East and Africa
- 10.4.1 South Africa
- 10.4.2 Saudi Arabia
- 10.4.3 U.A.E
- 10.4.4 Rest of Middle East and Africa
10.5 South and Central America
- 10.5.1 Brazil
- 10.5.2 Argentina
- 10.5.3 Rest of South and Central America

11. Industry Landscape

11.1 Mergers and Acquisitions
11.2 Agreements, Collaborations, Joint Ventures
11.3 New Product Launches
11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

12.1 Heat Map Analysis by Key Players
12.2 Company Positioning and Concentration

13. Hypopigmentation Disorder Treatment Market - Key Company Profiles

13.1 Allergan
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments

Note - Similar information would be provided for below list of companies